Can I Take CoQ10 with Jardiance (Empagliflozin)?

What Is Jardiance and How Does It Work?

Jardiance (empagliflozin) blocks sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing the kidneys to excrete roughly 60 to 90 g of glucose per day in urine. The FDA first approved empagliflozin for type 2 diabetes in 2014, then for heart failure with reduced ejection fraction in 2021, and for chronic kidney disease in 2023 [1].

Key Cardiovascular Trial Data

The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% versus placebo (HR 0.86, 95% CI 0.74 to 0.99, P<0.001) [2]. Cardiovascular death alone fell by 38%. These results established empagliflozin as a cardiometabolic agent, not merely a glucose-lowering drug.

Secondary Hemodynamic Effects

Beyond glucose control, empagliflozin produces a modest but measurable reduction in systolic blood pressure, averaging 3 to 5 mmHg in the EMPA-REG OUTCOME population [2]. The mechanism involves osmotic diuresis and natriuresis rather than direct vasodilation. These hemodynamic changes are the main reason any blood-pressure-lowering supplement, including CoQ10, warrants attention in patients on Jardiance.

What Is CoQ10 and Why Do Patients on Jardiance Often Take It?

CoQ10 (ubiquinone) is a fat-soluble benzoquinone synthesized endogenously in mitochondrial membranes. It shuttles electrons in the oxidative phosphorylation chain and serves as a membrane-bound antioxidant [3]. Plasma CoQ10 concentrations fall with age and are further suppressed by HMG-CoA reductase inhibitors (statins), which block the same mevalonate pathway used to synthesize CoQ10 [4].

The Statin-CoQ10 Connection in T2D Patients

Approximately 70% of adults with type 2 diabetes on SGLT2 inhibitors are co-prescribed a statin per observational data [5]. A 2018 meta-analysis of 6 randomized controlled trials (N=302) confirmed that statin therapy reduces plasma CoQ10 by roughly 16 to 54% depending on statin type and dose [4]. Patients who notice myalgia or fatigue on statins often ask whether CoQ10 supplementation helps, which is the most common reason the combination of CoQ10 and Jardiance arises clinically.

Does CoQ10 Replace a Depleted Pool?

Oral CoQ10 at 100 to 300 mg/day raises plasma ubiquinone concentrations measurably. A double-blind RCT (N=64) published in the European Journal of Nutrition found that 200 mg/day ubiquinol for 12 weeks raised plasma CoQ10 from a median of 0.8 micromol/L to 2.7 micromol/L [6]. Whether restoring plasma CoQ10 translates to reduced statin myopathy remains debated. The 2022 ACC/AHA guidelines on cholesterol do not yet endorse routine CoQ10 supplementation for statin myopathy, noting that evidence from large RCTs is insufficient [7].

Is There a Direct Drug-Supplement Interaction Between CoQ10 and Empagliflozin?

No published pharmacokinetic study documents a direct interaction. The two compounds use entirely different metabolic pathways.

Pharmacokinetic Profile of Empagliflozin

Empagliflozin is primarily metabolized via UGT1A3, UGT1A8, UGT1A9, and UGT2B7 glucuronidation pathways [1]. It is not a substrate of CYP450 enzymes in any clinically meaningful sense. Peak plasma concentration occurs at 1.5 hours post-dose, and the half-life is approximately 12 hours [1].

How CoQ10 Is Absorbed and Metabolized

CoQ10 is absorbed via micellar solubilization in the small intestine, incorporated into chylomicrons, and transported to the liver. It does not meaningfully induce or inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at doses used clinically [3]. Because empagliflozin bypasses CYP metabolism and CoQ10 does not modulate UGT enzymes, there is no documented pharmacokinetic collision between the two compounds.

What the Natural Medicines Database Says

The Natural Medicines Comprehensive Database, the primary reference used by clinical pharmacists, rates the CoQ10-empagliflozin interaction as "insufficient reliable evidence to rate." This is not a red flag. It reflects the absence of dedicated interaction studies, not a signal of harm.

Pharmacodynamic Considerations: Where Caution Is Warranted

Even without a pharmacokinetic interaction, two compounds can produce additive or antagonistic effects through overlapping biological actions. For CoQ10 and Jardiance, the relevant overlap is blood pressure.

CoQ10 and Blood Pressure: What the Evidence Shows

A 2007 meta-analysis of 12 clinical trials (N=362) found CoQ10 supplementation reduced systolic blood pressure by a mean of 11 mmHg and diastolic blood pressure by 7 mmHg in hypertensive patients [8]. The mechanism may involve improved vascular endothelial function and reduced oxidative stress rather than diuresis. A more recent 2023 Cochrane-style review of CoQ10 in hypertension confirmed modest antihypertensive effects but noted significant heterogeneity across studies [9].

Adding CoQ10 to Empagliflozin's Hemodynamic Effects

Jardiance already lowers systolic blood pressure by 3 to 5 mmHg on average [2]. For most patients, adding CoQ10 at 100 to 200 mg/day would produce a cumulative blood pressure reduction that is clinically modest and generally not dangerous. However, patients who are:

• already on ACE inhibitors, ARBs, or calcium-channel blockers
• volume-depleted from concurrent diuretic therapy
• elderly with orthostatic hypotension risk

...should discuss CoQ10 initiation with their prescriber. A symptomatic blood pressure drop can increase fall risk, particularly in older adults.

Glucose Metabolism: Is There Any Signal?

Some small studies suggest CoQ10 may modestly improve insulin sensitivity. A double-blind RCT in patients with type 2 diabetes (N=74) published in the European Journal of Nutrition found that 200 mg/day CoQ10 for 12 weeks reduced fasting glucose by approximately 8 mg/dL compared to placebo (P<0.05) [10]. The effect size is small and would be unlikely to cause hypoglycemia when combined with empagliflozin, which itself carries a low hypoglycemia risk as a monotherapy. The combination could theoretically amplify glucose-lowering in patients also on sulfonylureas or insulin, so those co-medications warrant disclosure.

Who Is Most Likely to Benefit from CoQ10 While on Jardiance?

Not every patient on Jardiance has equal reason to consider CoQ10. The following clinical profile describes patients for whom CoQ10 may offer the most relevant rationale.

Patients Co-Prescribed a Statin

As noted above, statins suppress endogenous CoQ10 synthesis via mevalonate pathway inhibition [4]. A patient taking empagliflozin plus atorvastatin 40 mg/day, for example, faces documented CoQ10 depletion. If that patient reports new myalgia or exercise intolerance after statin initiation, a trial of CoQ10 100 to 200 mg/day with food is a reasonable, low-risk intervention to discuss with their physician. The 2019 European Atherosclerosis Society consensus paper acknowledged CoQ10 depletion as a real statin side-effect mechanism, even while calling for larger RCTs before routine prescribing [11].

Patients with Heart Failure

Jardiance received FDA approval for heart failure with reduced ejection fraction (HFrEF) in 2021, and for heart failure with preserved ejection fraction (HFpEF) in 2022 [1]. The Q-SYMBIO trial (N=420) found CoQ10 300 mg/day reduced major adverse cardiovascular events in heart failure patients by 43% versus placebo over 2 years (HR 0.50, 95% CI 0.27 to 0.91, P<0.02) [12]. While Q-SYMBIO was conducted in patients not uniformly on SGLT2 inhibitors, the mechanistic rationale for CoQ10 in heart failure (improved mitochondrial energetics in cardiomyocytes) is plausible and not contradicted by empagliflozin's mechanism. Heart failure patients should discuss this with their cardiologist rather than self-initiating.

Patients Without a Statin or Heart Failure Indication

For patients taking Jardiance purely for type 2 diabetes without statin co-therapy and without heart failure, the case for CoQ10 is weaker. The supplement is generally safe, but evidence of net clinical benefit in this sub-group is thin.

Practical Dosing and Timing Guidance

Empagliflozin is typically taken once daily in the morning with or without food. CoQ10 is fat-soluble and absorbs best with a meal containing dietary fat.

Suggested Administration Approach

No dose-separation window is necessary because there is no pharmacokinetic interaction. A straightforward approach:

• Take empagliflozin 10 mg or 25 mg as prescribed, typically in the morning.
• Take CoQ10 100 to 200 mg with your largest meal of the day to maximize absorption.
• Ubiquinol (the reduced form) may offer modestly better bioavailability than ubiquinone in adults over 50, based on a comparative crossover study (N=12) showing roughly 2-fold higher plasma levels with ubiquinol [6].

Starting Dose and Titration

A starting dose of 100 mg/day is reasonable. Some cardiovascular studies used 200 to 300 mg/day. Doses above 300 mg/day have not demonstrated proportionally greater benefit and may not be necessary for most patients [8].

Monitoring Recommendations

Patients adding CoQ10 to a Jardiance regimen should pay attention to a short list of measurable parameters.

Blood Pressure Checks

Check home blood pressure once or twice daily for the first 2 to 4 weeks after starting CoQ10. If systolic blood pressure drops below 100 mmHg or dizziness occurs on standing, contact your prescriber. This is particularly relevant for patients on three or more antihypertensive agents.

Symptom Monitoring

Watch for lightheadedness, excessive fatigue, or palpitations in the first 4 weeks. These are unlikely but possible in volume-sensitive patients. Most people add CoQ10 without any perceptible change in how they feel.

Lab Monitoring

No additional laboratory testing is specifically required for the CoQ10-empagliflozin combination beyond the standard annual metabolic panel, HbA1c, and renal function tests already recommended for patients on empagliflozin. The FDA prescribing information for Jardiance recommends monitoring eGFR before initiating and periodically thereafter [1].

What the Guidelines Say About Empagliflozin Safety in Context

The 2023 American Diabetes Association Standards of Care describe SGLT2 inhibitors as first- or second-line agents for type 2 diabetes in patients with established cardiovascular disease, CKD, or heart failure, independent of HbA1c [13]. The ADA states: "In patients with T2D and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce cardiovascular and renal risk" [13].

The 2022 AHA/ACC Guideline for Heart Failure designates SGLT2 inhibitors as Class I, Level A evidence for patients with HFrEF to reduce hospitalizations and cardiovascular death [14]. Neither guideline addresses CoQ10 co-supplementation directly, which reflects the absence of trial data rather than a concern about harm.

Safety Summary: CoQ10 Toxicity Profile

CoQ10 has been used at doses up to 3,000 mg/day in clinical studies without serious adverse events [3]. The most commonly reported side effects at therapeutic doses (100 to 300 mg/day) are mild gastrointestinal symptoms such as nausea or loose stools, occurring in fewer than 1% of participants in controlled trials [3]. There is no documented hepatotoxicity, nephrotoxicity, or drug-induced coagulopathy with CoQ10 at standard doses. Patients on warfarin should note that a small number of case reports describe CoQ10 reducing warfarin's anticoagulant effect, likely due to structural similarity to vitamin K [3]. Empagliflozin does not affect coagulation, so this warfarin concern is not relevant to the Jardiance combination itself.